Skip to content

Studying the effects of dexamethasone in the prevention of nausea and vomiting and postoperative pain in patients undergoing abdominal hysterectomy

Comparative study of dexamethasone versus placebo in the prevention of nausea and vomiting and postoperative pain in patients undergoing abdominal hysterectomy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161220031487N8
Enrollment
102
Registered
2018-04-08
Start date
2016-03-19
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysterectomy. Acquired absence of genital organ(s)

Interventions

Intervention 1: Intervention group: Single dose of 8 mg intravenous dexamethasone infusion. Intervention 2: Control group: normal saline (2 ml).

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 30 years Candidate for abdominal hysterectomy Body mass index (BMI) from 20-35

Exclusion criteria

Exclusion criteria: Systemic disease such as diabetes, asthma or cancer History of allergy to dexamethasone Nausea and vomiting in 24 hours prior to operation Receiving anti-emetics 48 hours before operation Digestive system anomalies such as gastritis and esophagitis

Design outcomes

Primary

MeasureTime frame
Prevalence of nausea and vomiting. Timepoint: Measurement at 0? 2? 4? 6? 12 and 24 hours after operation. Method of measurement: The severity of nausea is from 0 to 10, a score of 0 indicates a lack of nausea, and 10 means a very severe nausea.;Severity of pain felt by patients. Timepoint: Measured at 0, 2, 4, 6, 12 and 24 hours after operation. Method of measurement: The severity of the pain felt by the patients is scored from 0 to 10, with zero indicating the absence of pain and 10 means a very severe pain.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahla Amirzargar

Iran University of Medical Sciences

shahlaamirzargar@yahoo.com+98 21 8214 1600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026